Skip to main content

Table 1 Anticancer activity evaluation of 2-AAPA against various human cancer cells

From: Microtubule S-glutathionylation as a potential approach for antimitotic agents

Cell line

IC50*(μM)

NCI/ADR-RES (ovarian cancer)

28 ± 1

OVCAR-3 (ovarian cancer)

33 ± 2

UACC-62 (melanoma)

22 ± 1

SK-MEL-2 (melanoma)

40 ± 9

NCI-H226 (lung cancer)

68 ± 4

UO-31 (kidney cancer)

44 ± 10

A431 (skin cancer)

73 ± 4

PC-3 (prostate cancer)

50 ± 12

MCF7 (breast cancer)

75 ± 5

GC3/c1 (colon cancer)

42 ± 1

  1. *IC50: concentration of a drug required to reduce cell growth by 50%. Cells were treated with 2-AAPA for 6 days. Cell survival rates were determined by the MTT assay. IC50 values were derived from corresponding dose–response curves. The data are presented as the mean ± SD of three independent experiments.